Molecular Partners AG

SWX:MOLN Stock Report

Market Cap: CHF 99.8m

Molecular Partners Valuation

Is MOLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MOLN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MOLN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOLN?

Key metric: As MOLN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MOLN. This is calculated by dividing MOLN's market cap by their current revenue.
What is MOLN's PS Ratio?
PS Ratio44.7x
SalesCHF 2.23m
Market CapCHF 99.79m

Price to Sales Ratio vs Peers

How does MOLN's PS Ratio compare to its peers?

The above table shows the PS ratio for MOLN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.7x
RLF Relief Therapeutics Holding
3.3xn/aCHF 27.9m
BSLN Basilea Pharmaceutica
3.2x3.16%CHF 660.0m
IDIA Idorsia
3.7x35.32%CHF 597.1m
SANN Santhera Pharmaceuticals Holding
4.6x48.73%CHF 180.2m
MOLN Molecular Partners
44.7x55.38%CHF 99.8m

Price-To-Sales vs Peers: MOLN is expensive based on its Price-To-Sales Ratio (44.7x) compared to the peer average (3.7x).

Price to Sales Ratio vs Industry

How does MOLN's PS Ratio compare vs other companies in the European Biotechs Industry?

53 CompaniesPrice / SalesEstimated GrowthMarket Cap
MOLN 44.7xIndustry Avg. 8.4xNo. of Companies53PS01224364860+
53 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MOLN is expensive based on its Price-To-Sales Ratio (44.7x) compared to the European Biotechs industry average (8.4x).

Price to Sales Ratio vs Fair Ratio

What is MOLN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOLN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio44.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MOLN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOLN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 2.99
CHF 9.50
+217.73%
57.89%CHF 15.00CHF 4.00n/a2
Jul ’26CHF 2.99
CHF 9.50
+218.26%
57.89%CHF 15.00CHF 4.00n/a2
Jun ’26CHF 3.20
CHF 9.50
+196.88%
57.89%CHF 15.00CHF 4.00n/a2
May ’26CHF 3.29
CHF 9.50
+189.19%
57.89%CHF 15.00CHF 4.00n/a2
Apr ’26CHF 3.43
CHF 9.50
+176.97%
57.89%CHF 15.00CHF 4.00n/a2
Mar ’26CHF 4.20
CHF 9.75
+132.14%
53.85%CHF 15.00CHF 4.50n/a2
Feb ’26CHF 4.80
CHF 9.75
+103.13%
53.85%CHF 15.00CHF 4.50n/a2
Jan ’26CHF 4.06
CHF 9.75
+140.15%
53.85%CHF 15.00CHF 4.50n/a2
Dec ’25CHF 5.20
CHF 9.75
+87.50%
53.85%CHF 15.00CHF 4.50n/a2
Nov ’25CHF 5.39
CHF 9.75
+80.89%
53.85%CHF 15.00CHF 4.50n/a2
Oct ’25CHF 4.01
CHF 9.75
+143.14%
53.85%CHF 15.00CHF 4.50n/a2
Sep ’25CHF 5.10
CHF 9.75
+91.18%
53.85%CHF 15.00CHF 4.50n/a2
Aug ’25CHF 5.95
CHF 9.35
+57.14%
60.43%CHF 15.00CHF 3.70n/a2
Jul ’25CHF 6.57
CHF 9.35
+42.31%
60.43%CHF 15.00CHF 3.70CHF 2.992
Jun ’25CHF 3.40
CHF 9.35
+175.00%
60.43%CHF 15.00CHF 3.70CHF 3.202
May ’25CHF 3.29
CHF 9.35
+184.19%
60.43%CHF 15.00CHF 3.70CHF 3.292
Apr ’25CHF 3.68
CHF 9.50
+158.50%
57.89%CHF 15.00CHF 4.00CHF 3.432
Mar ’25CHF 3.82
CHF 9.50
+148.69%
57.89%CHF 15.00CHF 4.00CHF 4.202
Feb ’25CHF 4.14
CHF 9.50
+129.47%
57.89%CHF 15.00CHF 4.00CHF 4.802
Jan ’25CHF 3.44
CHF 9.50
+176.16%
57.89%CHF 15.00CHF 4.00CHF 4.062
Dec ’24CHF 3.87
CHF 10.50
+171.67%
42.86%CHF 15.00CHF 6.00CHF 5.202
Nov ’24CHF 3.19
CHF 10.50
+229.67%
42.86%CHF 15.00CHF 6.00CHF 5.392
Oct ’24CHF 3.86
CHF 10.50
+172.37%
42.86%CHF 15.00CHF 6.00CHF 4.012
Sep ’24CHF 5.14
CHF 9.00
+75.10%
47.14%CHF 15.00CHF 6.00CHF 5.103
Aug ’24CHF 5.49
CHF 9.00
+63.93%
47.14%CHF 15.00CHF 6.00CHF 5.953
Jul ’24CHF 5.42
CHF 9.00
+66.05%
47.14%CHF 15.00CHF 6.00CHF 6.573
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
CHF 9.50
Fair Value
68.5% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/21 03:29
End of Day Share Price 2025/07/18 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Molecular Partners AG is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jo WaltonCredit Suisse
null nullCredit Suisse
Thomas KaufmannCredit Suisse